INS and obesity disorder: In addition, in the diet-induced obesity model as well as in ob/ob mice Marimastat treatment significantly lowered fasting glucose (P = 0.004 and P = 0.041, respectively; Figure 4C) and insulin (P = 0.013 and P = 0.039, respectively; Figure 4D) levels, resulting in improved surrogate markers for insulin sensitivity, as measured using the log(HOMA) (P<0.001 and P = 0.026, respectively; Figure 4E) and QUICKI (P<0.001 and P = 0.0307, respectively; Figure 4F) formulas.